已上市含麝香中成药再评价的分析探讨

Revaluation on post-marketing categories of Chinese patent drugs containing musk

目的:通过研究含麝香中成药的药品标准,提出对含麝香中成药再评价的建议。方法:对国家药品标准中所收载的含麝香的中成药进行统计,针对其命名、标准、用法用量、剂型和功能主治等进行分析。结果与结论:含麝香中成药处方、剂型、适应证、用法用量等不同程度地存在问题,有必要对其进行再评价并统一规范完善药品标准的相应项目。

Objective: To put forward revaluation suggestion of Chinese patent drugs containing musk by researching drug standards of Chinese patent drugs containing musk. Method: Analysis was carried out on the name, standard, dosage and administration, dosage form and indications etc., of the Chinese patent drugs containing musk included in national drug standard. Result & Conclusion: There are problems of prescriptions, dosage forms, indications, dosage and administration etc., in Chinese patent drugs containing musk. Revaluation is necessary, and the corresponding items of the drug should be unified, standard and completed.